Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia

A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Postherpetic Neuralgia

The purpose of this study is to determine whether KAI-1678 is effective in the treatment of postherpetic neuralgia pain

Inclusion Criteria:

• diagnosis of PHN with pain for at least 3 months after segmental herpes zoster eruption
• pain score at least 4 on 11-point numerical rating scale (0-10)
• stable doses of analgesic medications for at least 1 month"

Exclusion Criteria:

• diagnosis of PHN with pain for at least 3 months after segmental herpes zoster eruption
• pain score at least 4 on 11-point numerical rating scale (0-10)
• stable doses of analgesic medications for at least 1 month"